30th Edition of TOP500 List of World’s Fastest Supercomputers Released, Big Turnover Among the Top 10 Systems | TOP500 Supercomputing Sites:
Finally India into the top 10 of supercomputing!!
Check the news...
"For the first time ever, India placed a system in the Top 10. The Computational Research Laboratories, a wholly owned subsidiary of Tata Sons Ltd. in Pune, India, installed a Hewlett-Packard Cluster Platform 3000 BL460c system. They integrated this system with their own innovative routing technology and achieved 117.9 TFlop/s performance."
Some of the interesting aspects to ponder relevant to Computer Aided Drug Design(CADD)
Thursday, January 17, 2008
Trends in the globalization of clinical trials : Article : Nature Reviews Drug Discovery
Trends in the globalization of clinical trials : Article : Nature Reviews Drug Discovery
It's evident that clinical trials are among the top latest happening things in Indian pharmaceutical industry. In this nature article, India with 20% growth in clinical trials is ranked (16th) ahead of China (25th). But wait, China shows an amazing growth of 47%, the most by any countries. Keep watching, something is really happening around....
It's evident that clinical trials are among the top latest happening things in Indian pharmaceutical industry. In this nature article, India with 20% growth in clinical trials is ranked (16th) ahead of China (25th). But wait, China shows an amazing growth of 47%, the most by any countries. Keep watching, something is really happening around....
Wednesday, January 16, 2008
Patenting the drug targets: New horizon and new social/monetary impacts
Reach-through claims for drug target patents: Rx for pharmaceutical policy :
When a major chunk of scientific community debate for a free world (GNU), here comes a new development; patent the targets and earn money through the drugs acting on it.. Who'll finally pay for it? The unfortunate patients..
However this will be a motivating news to the biologist/pharmacologist who work hard to find novel targets but who are usually least benefited in monetary terms. It is crucial to make a fool-proof patent law in this regard. Otherwise, it'll hinder not only the scientific freedom but also treatment availability to the poor suffering patients.
When a major chunk of scientific community debate for a free world (GNU), here comes a new development; patent the targets and earn money through the drugs acting on it.. Who'll finally pay for it? The unfortunate patients..
However this will be a motivating news to the biologist/pharmacologist who work hard to find novel targets but who are usually least benefited in monetary terms. It is crucial to make a fool-proof patent law in this regard. Otherwise, it'll hinder not only the scientific freedom but also treatment availability to the poor suffering patients.
Monday, January 14, 2008
The Trouble with QSAR (or How I Learned To Stop Worrying and Embrace Fallacy)
The Trouble with QSAR (or How I Learned To Stop Worrying and Embrace Fallacy)
Interesting article!

The picture provided is hilarious :)
(*Image from ACS J. Chem. Inf. Model.)
Interesting article!

The picture provided is hilarious :)
(*Image from ACS J. Chem. Inf. Model.)
Subscribe to:
Posts (Atom)